Lung transplants from A2 donors to O recipients
Blood Group A2 Donor to Blood Group O Recipient Lung Transplantation
This study is testing if lung transplants from A2 blood type donors can safely help people with O blood type who are waiting for a transplant.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05581745 on ClinicalTrials.gov |
What this trial studies
This study investigates the feasibility and safety of lung transplants from blood group A2 donors to blood group O recipients. It aims to address the longer wait times and higher mortality rates faced by blood group O candidates by expanding the donor pool. The study will involve a prospective approach, assessing the outcomes of these ABO-incompatible transplants while utilizing peri-operative antibody-depleting therapies. This is the first prospective study of its kind worldwide, focusing on improving transplant accessibility for blood group O patients.
Who should consider this trial
Good fit: Ideal candidates for this study are first-time lung transplant recipients with blood group O and low pre-operative anti-A antibody titers.
Not a fit: Patients who may not benefit include those requiring re-transplants, multiorgan transplants, or those with a positive virtual crossmatch at the time of transplant.
Why it matters
Potential benefit: If successful, this approach could significantly reduce wait times and improve survival rates for blood group O lung transplant candidates.
How similar studies have performed: Other studies have shown success with ABO-incompatible kidney and liver transplants, but this approach for lung transplants is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * first lung transplant * blood group O recipient * low pre-operative anti-A antibody titers * consent to study participation Exclusion Criteria: * re-transplant * multiorgan transplant * positive virtual crossmatch at time of transplant
Where this trial is running
Toronto, Ontario
- Toronto General Hospital, University Health Network — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Shaf Keshavjee, MD MSc FRCSC FACS — University Health Network, Toronto
- Study coordinator: Sharaniyaa Balachandran
- Email: sharaniyaa.balachandran@uhn.ca
- Phone: 416-340-4800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.